当前位置: 首页 >> 检索结果
510. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
作者: Leila C Kahwati.;Cynthia Feltner.;Michael Halpern.;Carol L Woodell.;Erin Boland.;Halle R Amick.;Rachel Palmieri Weber.;Daniel E Jonas.
来源: JAMA. 2016年316卷9期970-83页
Five to ten percent of individuals with latent tuberculosis infection (LTBI) progress to active tuberculosis (TB) disease. Identifying and treating LTBI is a key component of the strategy for reducing the burden of TB disease.
511. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement.
作者: .;Kirsten Bibbins-Domingo.;David C Grossman.;Susan J Curry.;Linda Bauman.;Karina W Davidson.;John W Epling.;Francisco A R García.;Jessica Herzstein.;Alex R Kemper.;Alex H Krist.;Ann E Kurth.;C Seth Landefeld.;Carol M Mangione.;William R Phillips.;Maureen G Phipps.;Michael P Pignone.
来源: JAMA. 2016年316卷9期962-9页
Tuberculosis remains an important preventable disease in the United States. An effective strategy for reducing the transmission, morbidity, and mortality of active disease is the identification and treatment of latent tuberculosis infection (LTBI) to prevent progression to active disease.
512. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes.
作者: Joel G Ray.;Marian J Vermeulen.;Aditya Bharatha.;Walter J Montanera.;Alison L Park.
来源: JAMA. 2016年316卷9期952-61页
Fetal safety of magnetic resonance imaging (MRI) during the first trimester of pregnancy or with gadolinium enhancement at any time of pregnancy is unknown.
513. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
作者: Kevin J Whitehead.;Nathan B Sautter.;Justin P McWilliams.;Murali M Chakinala.;Christian A Merlo.;Maribeth H Johnson.;Melissa James.;Eric M Everett.;Marianne S Clancy.;Marie E Faughnan.;S Paul Oh.;Scott E Olitsky.;Reed E Pyeritz.;James R Gossage.
来源: JAMA. 2016年316卷9期943-51页
Epistaxis is a major factor negatively affecting quality of life in patients with hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Weber-Rendu disease). Optimal treatment for HHT-related epistaxis is uncertain.
514. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
作者: Sophie Dupuis-Girod.;Alexis Ambrun.;Evelyne Decullier.;Anne-Emmanuelle Fargeton.;Adeline Roux.;Valentine Bréant.;Bettina Colombet.;Sophie Rivière.;César Cartier.;Pascal Lacombe.;Thierry Chinet.;Sandra Blivet.;Jean-Hugues Blondel.;Brigitte Gilbert-Dussardier.;Xavier Dufour.;Justin Michel.;Jean-Robert Harle.;Patrick Dessi.;Frédéric Faure.
来源: JAMA. 2016年316卷9期934-42页
Epistaxis is the most frequent and disabling manifestation of hereditary hemorrhagic telangiectasia (HHT). The efficacy of intravenous bevacizumab (an anti-vascular endothelial growth factor monoclonal antibody) for epistaxis has been shown. However, the efficacy of intranasal bevacizumab has yet to be evaluated.
|